Probiotics and irritable bowel syndrome: rationale, putative mechanisms, and evidence of clinical efficacy - PubMed (original) (raw)
Review
Probiotics and irritable bowel syndrome: rationale, putative mechanisms, and evidence of clinical efficacy
Michael Camilleri. J Clin Gastroenterol. 2006 Mar.
Abstract
The irritable bowel syndrome (IBS) follows an acute, presumably infectious diarrheal illness in approximately 15% of patients. There may be a persistent, mild inflammatory state with changes in mucosal function or structure. Changes in the colonic bacterial flora reported in IBS seem related to predominant bowel. Colonic bacteria normally metabolize nutrients with the formation of gas and short chain fatty acids. The latter may induce propulsive contractions and accelerate colonic transit or they may enhance fluid and sodium absorption in the colon. This review addresses the mechanisms, rationale and current evidence for the efficacy of probiotics, including Lactobacilli, Bifidobacteria, and VSL#3, in the treatment of IBS. The mechanisms influenced by probiotics include immune function, motility, and the intraluminal milieu. Probiotics may suppress the low-grade inflammation associated with IBS or restore normal local immune function. Lactobacilli and Bifidobacteria subspecies are able to deconjugate and absorb bile acids, potentially reducing the colonic mucosal secretion of mucin and fluids that may contribute to functional diarrhea or IBS with diarrhea. Therapeutic trials show the potential benefit of Bifidobacteria or Lactobacilli species alone or in the specific probiotic combination, VSL#3, on symptoms in IBS. Colonic transit was retarded in IBS patients treated with VSL#3 without induction of significant changes in bowel function. In summary, probiotics are promising therapies in IBS.
Similar articles
- Treatment of irritable bowel syndrome with probiotics. An etiopathogenic approach at last?
Bixquert Jiménez M. Bixquert Jiménez M. Rev Esp Enferm Dig. 2009 Aug;101(8):553-64. doi: 10.4321/s1130-01082009000800006. Rev Esp Enferm Dig. 2009. PMID: 19785495 Review. - Probiotics and irritable bowel syndrome: rationale, mechanisms, and efficacy.
Camilleri M. Camilleri M. J Clin Gastroenterol. 2008 Sep;42 Suppl 3 Pt 1:S123-5. doi: 10.1097/MCG.0b013e3181574393. J Clin Gastroenterol. 2008. PMID: 18806702 Review. - Review article: probiotics and prebiotics in irritable bowel syndrome.
Spiller R. Spiller R. Aliment Pharmacol Ther. 2008 Aug 15;28(4):385-96. doi: 10.1111/j.1365-2036.2008.03750.x. Epub 2008 Jun 4. Aliment Pharmacol Ther. 2008. PMID: 18532993 Review. - Is there a role for probiotics in irritable bowel syndrome?
Camilleri M. Camilleri M. Dig Liver Dis. 2006 Dec;38 Suppl 2:S266-9. doi: 10.1016/S1590-8658(07)60007-3. Dig Liver Dis. 2006. PMID: 17259088 Review. - The effect of a multispecies probiotic mixture on the symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial.
Ki Cha B, Mun Jung S, Hwan Choi C, Song ID, Woong Lee H, Joon Kim H, Hyuk J, Kyung Chang S, Kim K, Chung WS, Seo JG. Ki Cha B, et al. J Clin Gastroenterol. 2012 Mar;46(3):220-7. doi: 10.1097/MCG.0b013e31823712b1. J Clin Gastroenterol. 2012. PMID: 22157240 Clinical Trial.
Cited by
- Acacia fiber or probiotic supplements to relieve gastrointestinal complaints in patients with constipation-predominant IBS: a 4-week randomized double-blinded placebo-controlled intervention trial.
JanssenDuijghuijsen L, van den Belt M, Rijnaarts I, Vos P, Guillemet D, Witteman B, de Wit N. JanssenDuijghuijsen L, et al. Eur J Nutr. 2024 Aug;63(5):1983-1994. doi: 10.1007/s00394-024-03398-8. Epub 2024 Apr 23. Eur J Nutr. 2024. PMID: 38653808 Free PMC article. Clinical Trial. - The use of Lactobacillus casei DG® prevents symptomatic episodes and reduces the antibiotic use in patients affected by chronic bacterial prostatitis: results from a phase IV study.
Cai T, Gallelli L, Cione E, Perletti G, Ciarleglio F, Malossini G, De Pretis G, Palmieri A, Mirone V, Bartoletti R, Johansen TEB. Cai T, et al. World J Urol. 2021 Sep;39(9):3433-3440. doi: 10.1007/s00345-020-03580-7. Epub 2021 Jan 13. World J Urol. 2021. PMID: 33442769 Free PMC article. Clinical Trial. - Effects of probiotic supplementation on post-infectious irritable bowel syndrome in rodent model.
Hong KB, Seo H, Lee JS, Park Y. Hong KB, et al. BMC Complement Altern Med. 2019 Jul 31;19(1):195. doi: 10.1186/s12906-019-2610-9. BMC Complement Altern Med. 2019. PMID: 31366385 Free PMC article. - Adaptation and Probiotic Potential of Lactobacilli, Isolated from the Oral Cavity and Intestines of Healthy People.
Chervinets Y, Chervinets V, Shenderov B, Belyaeva E, Troshin A, Lebedev S, Danilenko V. Chervinets Y, et al. Probiotics Antimicrob Proteins. 2018 Mar;10(1):22-33. doi: 10.1007/s12602-017-9348-9. Probiotics Antimicrob Proteins. 2018. PMID: 29164486 - Secretome of Intestinal Bacilli: A Natural Guard against Pathologies.
Ilinskaya ON, Ulyanova VV, Yarullina DR, Gataullin IG. Ilinskaya ON, et al. Front Microbiol. 2017 Sep 1;8:1666. doi: 10.3389/fmicb.2017.01666. eCollection 2017. Front Microbiol. 2017. PMID: 28919884 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources